Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.

BACKGROUND Many pediatric patients with inflammatory bowel disease (IBD) lose response to infliximab (IFX) within the first year, and achieving a minimal target IFX trough concentration is associated with higher remission rates and longer durability. Population pharmacokinetic (PK) modeling can predict trough concentrations for individualized dosing. THE OBJECT OF THIS STUDY WAS T o refine a population PK model that accurately predicts individual IFX exposure during maintenance therapy using longitudinal real-practice data. METHODS We exported data from the electronic health records of pediatric patients with IBD treated with originator IFX at a single center between January 2011 and March 2017. Subjects were divided into discovery and validation cohorts. A population PK model was built and then validated. RESULTS We identified 228 pediatric patients with IBD who received IFX and had at least 1 drug concentration measured, including 135 and 93 patients in the discovery and validation cohorts, respectively. Weight, albumin, antibodies to IFX (ATI) detected by a drug-tolerant assay, and erythrocyte sedimentation rate (ESR) were identified as covariates significantly associated with IFX clearance and incorporated into the model. The model exhibited high accuracy for predicting target IFX trough concentrations with an area under the receiver operating characteristic curve (AUROC) of 0.86 (95% confidence interval [CI], 0.81-0.91) for population-based predictions without prior drug-level input. Accuracy increased further for individual-based predictions when prior drug levels were known, with an AUROC of 0.93 (95% CI, 0.90-0.97). CONCLUSIONS A population PK model utilizing weight, albumin, ordinal drug-tolerant ATI, and ESR accurately predicts IFX trough concentrations during maintenance therapy in real-practice pediatric patients with IBD. This model, which incorporates dynamic clinical information, could be used for individualized dosing decisions to increase response durability.

[1]  D. Mould,et al.  Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System , 2018, Journal of clinical pharmacology.

[2]  N. Vande Casteele,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease , 2018, Clinical Pharmacokinetics.

[3]  S. Vermeire,et al.  Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial , 2017, Gut.

[4]  M. Benninga,et al.  Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease , 2017, Journal of pediatric gastroenterology and nutrition.

[5]  Siddharth Singh,et al.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. , 2017, Gastroenterology.

[6]  M. Wiese,et al.  Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies , 2017, The AAPS Journal.

[7]  D. Mould,et al.  A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease , 2017, Inflammatory bowel diseases.

[8]  S. Kugathasan,et al.  Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease , 2017, Journal of pediatric gastroenterology and nutrition.

[9]  K. Kolho,et al.  Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease , 2017, Journal of pediatric gastroenterology and nutrition.

[10]  K. Park,et al.  Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease , 2016, Journal of pediatric gastroenterology and nutrition.

[11]  A. Moss,et al.  Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.

[12]  D. Mould.  Why therapeutic drug monitoring is needed for monoclonal antibodies and how do we implement this? , 2016, Clinical pharmacology and therapeutics.

[13]  C. Ponsioen,et al.  Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  M. Dubinsky,et al.  Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients , 2016, The AAPS Journal.

[15]  G. Shankar,et al.  Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade® , 2016, The AAPS Journal.

[16]  C. Ponsioen,et al.  Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. , 2015, Gastroenterology.

[17]  K. Van Steen,et al.  Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  D. Mould,et al.  Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study , 2014, Inflammatory bowel diseases.

[19]  K. Kolho,et al.  Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report. , 2014, Journal of Crohn's & colitis.

[20]  G. Greenberg,et al.  The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease , 2014, Gut.

[21]  M. Dubinsky,et al.  Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease , 2014, Inflammatory bowel diseases.

[22]  Diane R. Mould,et al.  Dashboard Systems: Implementing Pharmacometrics from Bench to Bedside , 2014, The AAPS Journal.

[23]  P. Rutgeerts,et al.  Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial , 2014, Gut.

[24]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling Methods , 2014, CPT: pharmacometrics & systems pharmacology.

[25]  A. Griffiths,et al.  Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. , 2013, Journal of Crohn's & colitis.

[26]  P Chan,et al.  Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance , 2013, CPT: pharmacometrics & systems pharmacology.

[27]  L. Peyrin-Biroulet,et al.  Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study , 2013, Inflammatory bowel diseases.

[28]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods , 2013, CPT: pharmacometrics & systems pharmacology.

[29]  D. Mould,et al.  Anti‐TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics‐Based Dosing Paradigms , 2012, Clinical pharmacology and therapeutics.

[30]  F. Vasseur,et al.  Long‐term outcome of treatment with infliximab in pediatric‐onset Crohn's disease: A population‐based study , 2011, Inflammatory bowel diseases.

[31]  Honghui Zhou,et al.  Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. , 2011, Clinical therapeutics.

[32]  A. Griffiths,et al.  Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension , 2011, Current medical research and opinion.

[33]  A. Olson,et al.  Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. , 2010, International journal of clinical pharmacology and therapeutics.

[34]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[35]  M. Silverberg,et al.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.

[36]  A. Griffiths,et al.  Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. , 2007, Gastroenterology.

[37]  Lewis B. Sheiner,et al.  Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[38]  Roger W. Jelliffe,et al.  Individualizing Drug Dosage Regimens: Roles of Population Pharmacokinetic and Dynamic Models, Bayesian Fitting, and Adaptive Control , 1993, Therapeutic drug monitoring.

[39]  L B Sheiner,et al.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.